<DOC>
	<DOC>NCT02482077</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability, and efficacy of Sofosbuvir containing regimens in treatment-naive or treatment-experienced patients with HCV genotypes 2 infection.</brief_summary>
	<brief_title>Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>1. Age equal to or greater than 18 years, with chronic genotype 2 HCV infection; 2. Documented HCV treatmentnaïve or treatmentexperienced subjects who failed previous PEG+RBV regimen; 3. HCV RNA &gt; 10,000 IU/mL at Screening; 4. Screening laboratory values within defined thresholds 5. Use of two effective contraception methods if female of childbearing potential or sexually active male 1. Pregnant or nursing female or male with pregnant female partner; 2. HIV or chronic hepatitis B virus (HBV) infection; 3. Hematologic or biochemical parameters at Screening outside the protocolspecified requirements; 4. Active or recent history (≤ 1 year) of drug or alcohol abuse; 5. Hepatocellular carcinoma or other malignancy (with exception of certain resolved skin cancers).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>